Click here to view online. Add this email to your safelist.

AstraZeneca logo

Ultomiris recommended for approval in the EU by CHMP for children and adolescents with paroxysmal nocturnal haemoglobinuria

26 July 2021

Alexion’s Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria (PNH).

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2021

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.